Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521074 · ClinicalTrials.gov registry record · NA
Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 86
- Enrollment target
NCT05521074: Completed NA study, sponsored by Massachusetts General Hospital.
NCT05521074 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 86 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05521074, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 86 participants
- Enrollment target
Study Summary
The investigators want to learn more about how human beings learn not to fear and the impact of changing the fear network in the brain using transcranial Direct Current Stimulation (tDCS) in individuals with obsessive compulsive disorder (OCD). The investigators hope this study will help us understand how future treatments can help patients with OCD better control unwanted fear.
Primary Outcome
Greater reduction in the difference in frontomedial theta event-related spectral perturbation (ERSP) between CS+ vs CS- indicates more complete neural extinction of the conditioned fear response, reflecting diminished differential threat processing such that the previously conditioned stimulus is being processed more similarly to the safe stimulus.
Interventions
- DEVICE Sham tDCS
- DEVICE Active tDCS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2025-07-31 |
| Phase | NA |
What the finished NCT05521074 record still lists
NCT05521074 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham tDCS is the first listed.
NCT05521074 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05521074 about?
NCT05521074 is a clinical study titled "Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD". The investigators want to learn more about how human beings learn not to fear and the impact of changing the fear network in the brain using transcranial Direct Current Stimulation (tDCS) in individuals with obsessive compulsive disorder (OCD). The investigators hope this study will help us understa...
What is the current status of trial NCT05521074?
This trial is currently completed. It is a NA study. The enrollment target is 86 participants. The study started on 2022-09-15. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT05521074?
The interventions under investigation include: Sham tDCS (DEVICE), Active tDCS (DEVICE).
Who is sponsoring clinical trial NCT05521074?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05521074's enrollment target sits among peer trials
86 976th of 2000 higher than 1,021 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI